Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 3
1989 2
1990 2
1991 2
1992 3
1993 7
1994 2
1995 4
1997 4
1998 3
1999 6
2000 10
2001 9
2002 15
2003 18
2004 28
2005 27
2006 24
2007 15
2008 26
2009 18
2010 8
2011 27
2012 19
2013 18
2014 25
2015 17
2016 23
2017 21
2018 14
2019 27
2020 31
2021 29
2022 32
2023 22
2024 17
2025 25

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

524 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma.
Fukushima T, Numakura K, Shinohara M, Kawashima Y, Sekine Y, Mori K, Kobayashi M, Asanuma H, Ichiyama T, Sakurai H, Ozaki K, Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Sato S, Habuchi T, Ohyama C, Hatakeyama S. Fukushima T, et al. Among authors: habuchi t. Sci Rep. 2025 Jul 18;15(1):26127. doi: 10.1038/s41598-025-09806-1. Sci Rep. 2025. PMID: 40681533 Free PMC article.
Cross-organ hierarchy of HLA molecular mismatches in donor-specific antibody development in solid organ transplantations.
Hirata M, Tsukita K, Shindo T, Yagi S, Ito T, Tanaka S, Fujimoto R, Kayawake H, Nakamura K, Fujiyama N, Saito M, Yurugi K, Hishida R, Kato A, Kawaguchi A, Habuchi T, Kobayashi T, Date H, Hatano E. Hirata M, et al. Among authors: habuchi t. Cell Rep Med. 2025 Jun 17;6(6):102153. doi: 10.1016/j.xcrm.2025.102153. Epub 2025 May 30. Cell Rep Med. 2025. PMID: 40449481 Free PMC article.
Japanese clinical practice guidelines for prostate cancer 2023.
Kohjimoto Y, Uemura H, Yoshida M, Hinotsu S, Takahashi S, Takeuchi T, Suzuki K, Shinmoto H, Tamada T, Inoue T, Sugimoto M, Takenaka A, Habuchi T, Ishikawa H, Mizowaki T, Saito S, Miyake H, Matsubara N, Nonomura N, Sakai H, Ito A, Ukimura O, Matsuyama H, Hara I. Kohjimoto Y, et al. Among authors: habuchi t. Int J Urol. 2024 Nov;31(11):1180-1222. doi: 10.1111/iju.15545. Epub 2024 Jul 30. Int J Urol. 2024. PMID: 39078210
[A Case of Renal Anastomosing Hemangioma].
Sasaki Y, Kashima S, Koyama T, Hiroshima Y, Amano K, Takahashi S, Nara T, Koizumi A, Yamamoto R, Numakura K, Saito M, Narita S, Nanjo H, Satoh S, Habuchi T. Sasaki Y, et al. Among authors: habuchi t. Hinyokika Kiyo. 2022 Aug;68(8):265-269. doi: 10.14989/ActaUrolJap_68_8_265. Hinyokika Kiyo. 2022. PMID: 36071018 Free article. Japanese.
The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer.
Numakura K, Kobayashi M, Muto Y, Sato H, Sekine Y, Sobu R, Aoyama Y, Takahashi Y, Okada S, Sasagawa H, Narita S, Kumagai S, Wada Y, Mori N, Habuchi T. Numakura K, et al. Among authors: habuchi t. Curr Oncol. 2023 Sep 1;30(9):8092-8110. doi: 10.3390/curroncol30090587. Curr Oncol. 2023. PMID: 37754502 Free PMC article. Review.
Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.
Tanegashima T, Shiota M, Fujiyama N, Narita S, Habuchi T, Fukuchi G, Takamatsu D, Oda Y, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tokunaga S, Eto M. Tanegashima T, et al. Among authors: habuchi t. J Immunol. 2024 Jul 1;213(1):23-28. doi: 10.4049/jimmunol.2300308. J Immunol. 2024. PMID: 38758119 Free PMC article.
Primary resistance to nivolumab plus ipilimumab therapy affects second-line treatment outcomes in patients with metastatic renal cell carcinoma.
Mori K, Numakura K, Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Yamana K, Kandori S, Kimura T, Nishiyama N, Bando Y, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Kitamura H, Miyake H, Habuchi T. Mori K, et al. Among authors: habuchi t. Cancer Sci. 2025 Feb;116(2):444-452. doi: 10.1111/cas.16326. Epub 2024 Nov 17. Cancer Sci. 2025. PMID: 39550694 Free PMC article.
524 results